All Updates

All Updates

icon
Filter
Partnerships
Arvinas enters license agreement with Novartis to commercialize PROTAC androgen receptor degrader targeting prostate cancer
Precision Medicine
Apr 11, 2024
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Apr 11, 2024

Arvinas enters license agreement with Novartis to commercialize PROTAC androgen receptor degrader targeting prostate cancer

Partnerships

  • Arvinas has entered a partnership with Novartis for the development and global licensing of ARV-766, Arvinas' second-generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. This venture also led to the sale of Arvinas' AR-V7 preclinical program to Novartis.

  • As per the agreement, Novartis will be responsible for the development and commercialization of ARV-766 and will receive R&D, manufacturing, and commercialization rights for the preclinical AR-V7 program. Arvinas will be paid a USD 150 million upfront payment for the two programs and up to USD 1.01 billion in payments for development, regulatory, and commercial milestones and tiered royalties for ARV-766.

  • Arvinas is a clinical-stage biotechnology company specializing in developing therapies using its proprietary Proteolysis-Targeting Chimera (PROTAC) technology, which aims to degrade disease-causing proteins. Arvinas’ main focus is on oncology and neuroscience, with key drug developments including ARV-110 (Bavdegalutamide) for prostate cancer and ARV-471 for breast cancer currently in clinical trials​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.